7 completed. 7 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Hemophilia: new trials by email Literature Review of Hemophilia trials Research Report on Hemophilia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor STSP-0601 for Injection - Hemophilia | Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 25 | 2024-03-18 | 2025-01-22 |
| SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment SS109 - Male, Hemophilia A With Inhibitor | Phase 1 / Phase 2 | Completed | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 24 | 2023-10-12 | 2024-07-19 |
| Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor STSP-0601 for Injection - Hemophilia | Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 32 | 2023-01-09 | 2024-01-02 |
| KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia KN057 doseⅠ, KN057 dose Ⅱ, KN057 dose Ⅲ - Hemophilia | Phase 2 | Completed | Suzhou Alphamab Co., Ltd. | 24 | 2022-07-07 | 2024-12-30 |
| A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor STSP-0601 for Injection - Hemophilia | Phase 1 / Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 77 | 2021-10-12 | 2024-09-19 |
| Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B Fitusiran - Hemophilia | Phase 2 / Phase 3 | Completed | Genzyme, a Sanofi Company | 32 | 2020-01-28 | 2026-09-28 |
| Treatment of Hepatitis C in Hemophilic Patients With HIV Peginterferon alfa-2a, Ribavirin - HIV Infections, Hepatitis C | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 22 | 2002-03-01 | 2008-07-30 |
Hemophilia A (7) · HIV Infections (1) · Hepatitis C (1)
Blood Coagulation Disorders (7) · Blood Coagulation Disorders, Inherited (7) · Coagulation Protein Disorders (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Genetic Diseases, Inborn (7) · Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Hemorrhagic Disorders (7) · Blood-Borne Infections (1) · Communicable Diseases (1) · Digestive System Diseases (1) · Flaviviridae Infections (1) · Genital Diseases (1) · Hepatitis (1) · Hepatitis, Viral, Human (1)
Injections (3) · Ribavirin (1) · fitusiran (1) · peginterferon alfa-2a (1)
Staidson (Beijing) Biopharmaceuticals Co., Ltd (3) · Genzyme, a Sanofi Company (1) · Hangzhou Gensciences Biopharmaceutical Co., Ltd. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Suzhou Alphamab Co., Ltd. (1)
China (5) · United States (2) · Canada (1) · India (1) · Italy (1) · Spain (1) · Turkey (Türkiye) (1)
Lei Zhang, Ph.D (2) · Changcheng Zheng, Doctor (1) · Hu Zhou, Doctor (1) · Jing Sun, Doctor (1) · Kenneth E. Sherman, MD, PhD (1) · Lei Zhang, MD (1) · Renchi Yang, Doctor (1) · Shujie Wang, Doctor (1) · Xielan Zhao, Doctor (1) · Ziqiang Yu, Doctor (1)
PMID 41637644, PMID 15374882, PMID 17058240, PMID 36796484
2019 (1), R01AI049508 (1)